Ezatiostat-Lenalidomide Combo Well Tolerated, Effective in MDS Patients
Ezatiostat is well tolerated and active when used in combination with lenalidomide to treat myelodysplastic syndrome (MDS).
Hematologic Cancers
Ethnic Difference Found in Level of Adherence to Oral Mercaptopurine in ALL
The first study to demonstrate conclusively that adherence to oral mercaptopurine influences risk of relapse in children with acute lymphoblastic leukemia (ALL) also found an ethnic difference in relapse risk that differed by level of adherence.
Lenalidomide Improves Disease-Free Survival in Multiple Myeloma
Maintenance therapy that included lenalidomide extended progression-free survival (PFS) in patients with multiple myeloma.
Protein Drives Tumorigenesis in B-Cell Tumors
CD19 is a major driver of tumorigenesis in B-cell tumors.
SAFETY ALERT: New Malignancy Risk with Revlimid
The FDA notified the public of an increased risk of second primary malignancies in patients with newly diagnosed multiple myeloma who received Revlimid (lenalidomide capsules; Celgene).
Deferasirox Decreases Serum Ferritin, Iron in RBC Transfusion-Dependent MDS
The 3-year, prospective, multicenter trial administered deferasirox at a starting dose of 20mg/kg (with dose escalation up to 40mg/kg/day permitted) to 173 patients with serum ferritin levels of ≥1,000µg/L who had received ≥20 units of RBCs with ongoing transfusion requirements.
Chemo Combination Promising for Multiple Myeloma
Elotuzumab, lenalidomide, low-dose dexamethasone well tolerated in relapsed/refractory MM.
Celgene Submits NDA for Pomalidomide for Multiple Myeloma
According to the International Myeloma Foundation, no new agents have been approved for multiple myeloma in nearly 6 years.
New Assay Available for Genetic Variants of Leukemia
Using this sequence-based assay, researchers will be able to investigate the human TET2, CBL, KRAS and RUNX1 genes, which are known to be associated with developmental defects, disease progression, and residual disease in a variety of leukemias and myeloid malignancies.
Pediatric Regimen Beats Adult Chemo for Young Adults With ALL
Lower mortality, improved remission and event-free survival rates, lower relapse rates.
- Loading...
Loading...
Loading... 
Loading...